MSU to felicitate Padma awardees, UPSC achievers
Vadodara: Maharaja Sayajirao University (MSU) will felicitate Padma Shri awardees and achievers of the Union Public Service Commission (UPSC) examinations who are associated with the institution.
A felicitation ceremony will be held on Thursday to honour them, including three Padma Shri recipients and two outstanding performers in the UPSC 2025 examinations.
Among those to be honoured is Ajay V Bhatt, the visionary behind the revolutionary Universal Serial Bus (USB) technology, who was awarded the Padma Shri for his contributions to science and technology. Bhatt is an alumnus of MSU's Faculty of Technology and Engineering.
The university will also felicitate Ratan Kumar Parimoo, a nonagenarian artist and eminent art historian closely associated with the Faculty of Fine Arts. In addition, Suresh Harilal Soni, founder of the Sabarkantha-based Sahyog Trust, will be honoured for his tireless efforts in supporting people with leprosy and physical disabilities.
The ceremony will also recognize two remarkable UPSC achievers: Harshita Goyal, who secured AIR 2 in the civil services examination and Bhavesh Royda, who attained AIR 86 in the Indian Forest Service examination.
"The university community will come together to celebrate the inspiring journeys and accomplishments of these individuals," said a university official.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
Time of India
3 hours ago
- Time of India
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda HYDERABAD: Dr Reddy's Laboratories has entered into a collaboration and license agreement with Iceland-based biotech player Alvotech for the co-development, manufacturing and commercialiation of a biosimilar of Merck Sharp & Dohme's blockbuster drug Keytruda (pembrolizumab). Keytruda, which is used for the treatment of various types of cancer, clocked sales of over US$29.5 billion in 2024. The collaboration will combine Dr Reddy's and Alvotech's capabilities in biosimilars to speed up the development process and extend the global reach of the biosimilar candidate. As per the agreement, the two companies will share the costs and responsibilities for jointly developing and manufacturing the biosimilar candidate and subject to certain exceptions, each company will have the right to commercialise the product globally, Dr Reddy's said on Thursday. 'The agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide,' said Róbert Wessman, chairman & CEO, Alvotech. Dr Reddy's CEO, Erez Israeli, said the pact demonstrates the company's ability to develop and manufacture high-quality and affordable treatment options for patients worldwide. 'Oncology has been a top focus therapy area for us, and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Israeli added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
India Today
3 hours ago
- India Today
‘Eco-friendly bakra' for Id? What a Bhopal Hindu group's drive is all about
A Bhopal-based Hindu outfit that claims to represent Sanatan followers has prepared what it calls 'eco-friendly bakras' ahead of Bakrid and appealed to the Muslim community to 'sacrifice' these instead of living male Tiwari of the Sanskriti Bachao Manch told INDIA TODAY that Hindus are often reminded that their major festivals, such as Holi, Diwali and Ganesh Puja, add to environmental degradation. 'We have started using dry colours and organic gulal on Holi; we are using Ganesh idols made from eco-friendly material; and we have also reduced sound and air pollution by bursting fewer crackers on Diwali. We now appeal to the Muslim community to shun the sacrifice of animals and instead perform symbolic sacrifices,' said Tiwari, adding that the onus of being environment-friendly was on all 'eco-friendly bakra' being pitched is a life-size model of a goat. It is made of mud with hair plastered on it. How has the response to Sanskriti Bachao Manch's appeal been? Well, the 'eco-friendly bakras' have not found any takers yet in claimed he wanted to retail the models at half the cost price of Rs 2,000, the subsidy aimed at promoting the concept. When asked if he had the same advice for those Hindus who offer animal sacrifices, Tiwari said the practice of 'bali' (sacrifice) had waned and it was mostly being done symbolically using a pumpkin instead of an animal. 'We are even against meat shops and killings of any kind, including by Hindus,' he said. Tiwari has four 'eco-friendly bakra' models in his inventory, but said he could supply more at short notice if orders were placed. 'I also appeal to Hindus not to sell goats on Id,' he to India Today Magazine
